486 related articles for article (PubMed ID: 23142525)
21. Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer's Disease and in Down Syndrome Dementia.
Raha-Chowdhury R; Henderson JW; Raha AA; Vuono R; Bickerton A; Jones E; Fincham R; Allinson K; Holland A; Zaman SH
J Alzheimers Dis; 2019; 69(1):91-109. PubMed ID: 30909239
[TBL] [Abstract][Full Text] [Related]
22. Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease.
Ma RH; Zhang Y; Hong XY; Zhang JF; Wang JZ; Liu GP
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):307-312. PubMed ID: 28585125
[TBL] [Abstract][Full Text] [Related]
23. Embryonic stem cell-based modeling of tau pathology in human neurons.
Mertens J; Stüber K; Poppe D; Doerr J; Ladewig J; Brüstle O; Koch P
Am J Pathol; 2013 May; 182(5):1769-79. PubMed ID: 23499461
[TBL] [Abstract][Full Text] [Related]
24. microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.
Chaves JCS; Machado FT; Almeida MF; Bacovsky TB; Ferrari MFR
Neurosci Lett; 2020 Jan; 714():134541. PubMed ID: 31605772
[TBL] [Abstract][Full Text] [Related]
25. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.
Butterfield DA; Di Domenico F; Swomley AM; Head E; Perluigi M
Biochem J; 2014 Oct; 463(2):177-89. PubMed ID: 25242166
[TBL] [Abstract][Full Text] [Related]
26. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX
J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379
[TBL] [Abstract][Full Text] [Related]
27. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
28. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
Xie Y; Tan Y; Zheng Y; Du X; Liu Q
J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
[TBL] [Abstract][Full Text] [Related]
29. Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome.
Park J; Yang EJ; Yoon JH; Chung KC
Mol Cell Neurosci; 2007 Oct; 36(2):270-9. PubMed ID: 17720532
[TBL] [Abstract][Full Text] [Related]
30. Neural stem cells reduce hippocampal tau and reelin accumulation in aged Ts65Dn Down syndrome mice.
Kern DS; Maclean KN; Jiang H; Synder EY; Sladek JR; Bjugstad KB
Cell Transplant; 2011; 20(3):371-9. PubMed ID: 20875225
[TBL] [Abstract][Full Text] [Related]
31. Insights from Drosophila models of Alzheimer's disease.
Cowan CM; Shepherd D; Mudher A
Biochem Soc Trans; 2010 Aug; 38(4):988-92. PubMed ID: 20658990
[TBL] [Abstract][Full Text] [Related]
32. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome.
Cataldo AM; Petanceska S; Peterhoff CM; Terio NB; Epstein CJ; Villar A; Carlson EJ; Staufenbiel M; Nixon RA
J Neurosci; 2003 Jul; 23(17):6788-92. PubMed ID: 12890772
[TBL] [Abstract][Full Text] [Related]
33. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease.
Chiasseu M; Alarcon-Martinez L; Belforte N; Quintero H; Dotigny F; Destroismaisons L; Vande Velde C; Panayi F; Louis C; Di Polo A
Mol Neurodegener; 2017 Aug; 12(1):58. PubMed ID: 28774322
[TBL] [Abstract][Full Text] [Related]
34. Cryo-EM structures of amyloid-β and tau filaments in Down syndrome.
Fernandez A; Hoq MR; Hallinan GI; Li D; Bharath SR; Vago FS; Zhang X; Ozcan KA; Newell KL; Garringer HJ; Jiang W; Ghetti B; Vidal R
Nat Struct Mol Biol; 2024 Jun; 31(6):903-909. PubMed ID: 38553642
[TBL] [Abstract][Full Text] [Related]
35. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention.
Head E; Lott IT; Patterson D; Doran E; Haier RJ
J Alzheimers Dis; 2007 Mar; 11(1):61-76. PubMed ID: 17361036
[TBL] [Abstract][Full Text] [Related]
36. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.
Terwel D; Dewachter I; Van Leuven F
Neuromolecular Med; 2002; 2(2):151-65. PubMed ID: 12428809
[TBL] [Abstract][Full Text] [Related]
37. Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer's Disease Associated with Down Syndrome.
Ichimata S; Martinez-Valbuena I; Lee S; Li J; Karakani AM; Kovacs GG
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511361
[TBL] [Abstract][Full Text] [Related]
38. Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation.
Lee YH; Im E; Hyun M; Park J; Chung KC
J Biol Chem; 2021; 296():100245. PubMed ID: 33380426
[TBL] [Abstract][Full Text] [Related]
39. Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies.
Maloney MT; Bamburg JR
Mol Neurobiol; 2007 Feb; 35(1):21-44. PubMed ID: 17519504
[TBL] [Abstract][Full Text] [Related]
40. SorLA deficiency dissects amyloid pathology from tau and cholinergic neurodegeneration in a mouse model of Alzheimer's disease.
Capsoni S; Carlo AS; Vignone D; Amato G; Criscuolo C; Willnow TE; Cattaneo A
J Alzheimers Dis; 2013; 33(2):357-71. PubMed ID: 22986780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
